250
Participants
Start Date
August 26, 2021
Primary Completion Date
November 28, 2025
Study Completion Date
November 28, 2025
RO7623066
Administered orally in capsule
Olaparib
"Administered orally.~Dose levels and schedules will be selected based on integration of preclinical data as well as clinical PK, safety, efficacy, and PD/biomarker data (as appropriate) from the dose escalation cohorts."
Carboplatin
Administered intravenously.
University of Virginia Health System, Charlottesville
The Ohio State University Comprehensive Cancer Center, Columbus
Cleveland Clinic,, Cleveland
South Texas Accelerated Research Therapeutics (START) - Midwest Location, Grand Rapids
University of Oklahoma Health Sciences Center, Oklahoma City
Mary Crowley Medical Research Center, Dallas
University of California Irvine Medical Center, Orange
Oregon Health & Science University, Portland
South Texas Accelerated Research Therapeutics (START), San Antonio
Yale School of Medicine, New Haven
Barbara Ann Karmanos Cancer Institute, Detroit
Dana-Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Rhode Island Hospital, Providence
The University of Texas MD Anderson Cancer Center, Houston
Hoffmann-La Roche
INDUSTRY